Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer-Reference-Cited by-同舟云学术

Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer

Published:2023-02 Issue:1 Volume:5 Page:85-98
ISSN:2666-0873
Container-title:JACC: CardioOncology
language:en
Short-container-title:JACC: CardioOncology

Author:

Waliany Sarah^ORCID,Caswell-Jin Jennifer,Riaz Fauzia,Myall Nathaniel,Zhu Han,Witteles Ronald M.,Neal Joel W.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Oncology

Reference56 articles.

1. Breast cancer statistics, 2019;DeSantis;CA Cancer J Clin,2019

2. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures;Wirapati;Breast Cancer Res,2008

3. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues;Owens;Clin Breast Cancer,2004

4. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer;Yano;Oncol Rep,2006

5. Correlation between HER2/neu overexpression/amplification and clinicopathologic parameters in advanced gastric cancer (AGC) patients (pts): a prospective study;Gravalos;J Clin Oncol,2006

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial;British Journal of Cancer;2024-06-21

2. Breast Cancer and Therapy-Related Cardiovascular Toxicity;Journal of Breast Cancer;2024

3. Research Progress on the Cardiotoxicity of EGFR-TKIs in Non-Small Cell Lung Cancer;Current Treatment Options in Oncology;2023-12

4. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS);BMC Pharmacology and Toxicology;2023-11-13

5. Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report;Case Reports in Oncology;2023-10-11